Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Amato

Showing results (341-350 of 353) with videos related to

Pageof 36
Sort By:
Cancers|August 9, 2020
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced MelanomaNabanita Mukherjee, Carol M Amato, Jenette Skees, et al.
Pharmacotherapy|December 29, 2000
Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical CentersS L Ellis, B L Carter, D C Malone, et al.
Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada|May 18, 2018
Q fever outbreak among travelers to Germany associated with live cell therapy - United States and Canada, 2014: a co-publicationM P Robyn, A P Newman, M Amato, et al.
Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanomaNikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.
Cell Death & Disease|June 10, 2020
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsNabanita Mukherjee, Jenette Skees, Kaleb J Todd, et al.
Clinical & Translational Immunology|January 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patientsVictoria M Vorwald, Dana M Davis, Robert J Van Gulick, et al.
Melanoma Research|March 16, 2017
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanomaJennifer D Hintzsche, Nicholas T Gorden, Carol M Amato, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Pageof 36

Showing results (341-350 of 353) with videos related to

Sort By:
Pageof 36
Cancers|August 9, 2020
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced MelanomaNabanita Mukherjee, Carol M Amato, Jenette Skees, et al.
Pharmacotherapy|December 29, 2000
Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical CentersS L Ellis, B L Carter, D C Malone, et al.
Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada|May 18, 2018
Q fever outbreak among travelers to Germany associated with live cell therapy - United States and Canada, 2014: a co-publicationM P Robyn, A P Newman, M Amato, et al.
Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanomaNikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.
Cell Death & Disease|June 10, 2020
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsNabanita Mukherjee, Jenette Skees, Kaleb J Todd, et al.
Clinical & Translational Immunology|January 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patientsVictoria M Vorwald, Dana M Davis, Robert J Van Gulick, et al.
Melanoma Research|March 16, 2017
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanomaJennifer D Hintzsche, Nicholas T Gorden, Carol M Amato, et al.
Journal of Medicinal Chemistry|February 17, 2006
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptorsSylvester R Klutchko, Hairong Zhou, R Thomas Winters, et al.
Pageof 36